Checkpoint Capital L.P. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Checkpoint Capital L.P. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 157,514 shares of the company’s stock, valued at approximately $1,936,000. Stoke Therapeutics accounts for 1.0% of Checkpoint Capital L.P.’s investment portfolio, making the stock its 13th largest position.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new stake in Stoke Therapeutics in the 2nd quarter worth approximately $19,835,000. SG Americas Securities LLC lifted its stake in Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock worth $927,000 after acquiring an additional 58,943 shares during the period. Vanguard Group Inc. boosted its holdings in Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after acquiring an additional 67,052 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in Stoke Therapeutics by 54.3% in the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock valued at $1,266,000 after acquiring an additional 36,240 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the period.

Insider Activity at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 17.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 11.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

STOK has been the topic of a number of research reports. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Stock Performance

STOK stock opened at $12.11 on Monday. The firm has a market capitalization of $641.47 million, a price-to-earnings ratio of -5.77 and a beta of 0.95. The firm has a 50 day moving average price of $12.44 and a 200-day moving average price of $13.78. Stoke Therapeutics, Inc. has a 52-week low of $3.77 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.